{
    "id": 29049,
    "fullName": "SPOP mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SPOP mutant indicates an unspecified mutation in the SPOP gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 8405,
        "geneSymbol": "SPOP",
        "terms": [
            "SPOP",
            "BTBD32",
            "TEF2"
        ]
    },
    "variant": "mutant",
    "createDate": "12/02/2018",
    "updateDate": "12/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16440,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Zytiga (abiraterone) treatment was associated with better responses as measured by 50% PSA falls (p=0.03) and decreased likelihood of progression (odds ratio 14.5, p=0.001) in patients with castration-resistant hormone-naive prostate cancer harboring SPOP mutations compared to patients with wild-type SPOP (PMID: 30068710).",
            "molecularProfile": {
                "id": 30978,
                "profileName": "SPOP mutant"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13052,
                    "pubMedId": 30068710,
                    "title": "SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30068710"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15320,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, prostate cancer patients with CDH1 loss and mutated SPOP, had a higher likelihood of favorably responding to Zytiga (abiraterone) (PMID: 30068710).",
            "molecularProfile": {
                "id": 30980,
                "profileName": "CDH1 loss SPOP mut"
            },
            "therapy": {
                "id": 1805,
                "therapyName": "Abiraterone",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13052,
                    "pubMedId": 30068710,
                    "title": "SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30068710"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30978,
            "profileName": "SPOP mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30980,
            "profileName": "CDH1 loss SPOP mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}